300
Participants
Start Date
December 14, 2018
Primary Completion Date
September 21, 2024
Study Completion Date
October 1, 2024
Secukinumab
Secukinumab : 150 mg per week for 5 weeks, and then every month by subcutaneous injection
TNF blocker
"TNF blocker (originator or biosimilar) :~* infliximab: 5mg/kg per IV infusion at weeks 0, 2, 6, and then every 6 weeks,~* etanercept: 50mg per week in subcutaneous injection,~* adalimumab: 40mg every other week in subcutaneous injection,~* certolizumab: 400mg every other week 3 times, and then 200mg every other week or 400mg per month in subcutaneous injections,~* golimumab: 50mg every month in subcutaneous injection, in case of overweight (\>100kg) an inadequate response, 100mg every month is allow."
blood specimen
Blood specimen at each visits for measurement of bDMARS blockers concentration and anti-drug antibody concentration
CHU Saint-Etienne, Saint-Etienne
CHU STRASBOURG - Hautepierre, Strasbourg
CHU d'Angers, Angers
CHRU Besançon, Besançon
APHP- Hôpital Avicenne, Bobigny
CHU Bordeaux, Bordeau
CHRU Brest, Brest
CHU Clermont-Ferrand, Clermont-Ferrand
CHU de Grenoble Alpes, Grenoble
CHD Vendée, La Roche-sur-Yon
CH Le Mans, Le Mans
CHRU Lille, Lille
Hôpital Saint-Philibert, Lomme
CH Lyon SUD, Lyon
Hôpital Edouard Herriot, Lyon
CHRU Montpellier, Montpellier
CHU Montpellier - 2 - Unité Clinique thérapeutique des Maladies Ostéo-Articulaires, Montpellier
CHU Nancy, Nancy
CHU de Nantes, Nantes
CHU de Nice, Nice
CHR d'Orléans, Orléans
APHP - Hôpital Ambroise Paré, Paris
APHP - Hôpital Bichat, Paris
APHP - Hôpital Cochin, Paris
APHP - Hôpital Henri Mondor, Paris
APHP - Hôpital Lariboisière, Paris
APHP - Hôpital Pitié-Salpétrière, Paris
APHP - Hôpital Saint-Antoine, Paris
APHP - Kremlin-Bicêtre, Paris
CHU de Poitiers, Poitiers
CHU Reims, Reims
CHU de Rouen, Rouen
CHU Toulouse, Toulouse
CHRU Tours, Tours
CH Princesse de Grace, Monaco
Ministry of Health, France
OTHER_GOV
Centre Hospitalier Universitaire de Saint Etienne
OTHER